[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chong Kun Dang Pharmaceutical\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":305},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,45,69,93,119,143,166,188,210,234,256,283],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100626704","phase-1-a-first-in-human-study-of-ckd-703-in-advanced-solid-tumors-and-non-small-cell-lung-cancer-100626704",false,"NCT07439094","A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","A First-in-Human, Multicenter, Open-Label, Phase 1\u002F2a Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Males and females ≥ 19-year-old\n* Part 1 : Solid tumors including NSCLC for which standard therapy has failed or was not tolerated, and no other effective therapy exists\n* Part 2 : Histologically or cytologically documented c-Met overexpressing nonsquamous NSCLC having failed at least 1 line of SoC therapy (platinum-based chemotherapy and\u002For immune checkpoint inhibitor).\n* Part 3 : Histologically or cytologically documented c-Met expressing solid tumors for which standard therapy has failed or was not tolerated.\n* In all parts of the study, subjects with NSCLC with documented actionable genetic alterations must have failed at least 1 line of country-level approved targeted therapies\n* Life expectancy ≥ 12 weeks as judged by the Investigator\n* Documented progressive and measurable disease as defined by RECIST 1.1\n* ECOG Performance Status 0 or 1\n\nExclusion Criteria:\n\n* Subject has received radiation therapy to the lung \\\u003C 6 months prior to the first dose of study drug\n* Prior radiotherapy to ≥ 25% of bone marrow\n* Anticancer systemic therapy such as immunotherapy, biologic, cytotoxic chemotherapy, or any investigational therapy (including cell therapy or gene therapy) within a period of 28 days prior to the first dose of study drug. Any anticancer therapy small molecule (eg. kinase inhibitor) or herbal therapy within 14 days prior to the first dose of study drug\n* Prior c-Met-targeted antibody therapy or any MMAE-containing ADC (prior c-Met targeting small molecules are allowed)\n* Use of strong P-gp and\u002For CYP3A4\u002F5 inducers within 21 days prior or strong P-gp and\u002For CYP3A4\u002F5 inhibitors within 14 days prior to the first dose of study drug\n* Use of sensitive CYP3A4\u002F5 substrate within 3 days or 5 times half-life prior to the first dose of study drug.\n* Evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis that required treatment with systemic steroids within 12 months of the planned first dose of the study drug\n* History of drug induced interstitial lung disease\n* Prior or active ocular or corneal disease based on ophthalmic evaluation (slit lamp and visual acuity)\n* Prior Grade 3 neuropathy or chronic Grade 2 neuropathy","ALL","19 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a Phase 1\u002F2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer.\n\nCKD-703 is composed of a c-Met-targeting monoclonal antibody (mAb) coupled to a cytotoxic payload consisting of the anti-microtubule drug monomethyl auristatin E (MMAE); thus, CKD-703 is a novel ADC offering a highly targeted approach with potential improvement of efficacy while reducing off-target effects for patients with NSCLC and other cancers.",[27,28],"Advanced Solid Tumors","Non-Small Cell Lung Cancer",[30,31,27,28],"c-Met","CKD-703","RECRUITING","2026-04-23",{"date":35,"type":36},"2026-04-27","ACTUAL",{"date":38,"type":36},"2026-04-16",{"date":40,"type":20},"2029-12",{"name":42,"class":43},"Chong Kun Dang Pharmaceutical","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100633858","phase-1-study-of-ckd-215-and-d215-in-adults-with-brca-mutated-advanced-ovarian-fallopian-tube-or-primary-peritoneal-cancer-100633858","NCT07532148","Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","A Multicenter, Randomized, Open-Label, 2-Period Crossover Study to Evaluate Pharmacokinetics, Safety, and Tolerability of CKD-215 and D215 in Adults With Advanced BRCA-Mutated Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Inclusion Criteria:\n\n* Between 19 aged and 75 aged in patients with advanced BRCA-mutated high-grade epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer\n* 18.0kg\u002Fm2≤body mass index(BMI)≤28.0kg\u002Fm2\n\nExclusion Criteria:\n\n* Have a gastrointestinal disease(Crohn's disease, ulcer etc.) history that can effect drug absorption or surgery\n* Patients with central nervous system metastases, unless clinically stable after treatment\n* CTCAE Grade 3 or higher adverse events(e.g., anemia, neutropenia, dysgeusia, cough, leukopenia, thrombocytopenia) related to D215\n* Subjects who are unable to participate in this clinical trial at the discretion of the investigator","FEMALE","75 Years",{"count":55,"type":20},24,[23],"Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215",[59],"Ovarian Cancer","NOT_YET_RECRUITING","2026-04-09",{"date":63,"type":36},"2026-04-15",{"date":65,"type":20},"2026-06",{"date":67,"type":20},"2027-08",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100624061","phase-1-a-clinical-trial-to-compare-and-evaluate-evaluate-the-pharmacokinetics-and-safety-of-ckd-846-100624061","NCT07404735","A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846","A Randomized, Open-label and Parallel Study to Evaluate the Pharmacokinetics and Safety of CKD-846 in Healthy Male Subjects","Inclusion Criteria:\n\n1. Healthy man aged between 19 to 55 at screening\n2. Weight ≥ 55kg\n3. Body mass index (BMI) of 18.5 to 27.0kg\u002Fm2\n4. Those who agree to contraception from the first Investigational Product(IP) dosing day till 6 months after the last dosing day and decide not to provide sperm during the participation of clinical trial\n5. Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial\n\nExclusion Criteria:\n\n1. Those who have clinically significant disease or medical history of Hepatopathy, Renal, Neurological, Immunity, Respiratory, Endocrine, urinary, tumor or Psychical disorder\n2. Those who have a history of clinically significant cardiovascular diseases such as myocardial infarction, angina pectoris, ventricular arrhythmia, heart failure, left ventricular outflow tract stenosis, stroke, and transient ischemic attack within 2 years prior to the first administration of the investigational drug\n3. Those with eye diseases including genetic degenerative retinal diseases, including retinitis pigmentosa\n4. Those with a past history of erection lasting more than 4 hours and priapism while taking PDE5 inhibitors such as tadalafil\n5. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption\n6. Persons with a history of clinically significant hypersensitivity to drugs or additives, including ingredients of clinical investigational drugs\n7. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n8. A person who is judged to be unsuitable as a test subject in a screening test conducted within 28 days before administration of the investigational drug\n9. Those who has a drug abuse history within one year or positive reaction on urine drug screening test.\n10. Those who has taken over-the-counter or prescription drugs, excluding topical agents without significant systemic absorption, within a specified period of time and the administered drug is judged to have an effect on this test or may affect the safety of the subject\n11. People who need to take nitrate preparations or nitric oxide donors etc. regularly or intermittently during the clinical trial period\n12. Those who continuously smoke excessively or consume caffeine or alcohol\n13. A person who consumed food containing grapefruit within 7 days before the first administration of the investigational drug\n14. Persons who participated in another clinical trial (including bioequivalence test) and received an investigational drug within 180days prior to the date of first administration of the investigational drug\n15. Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days\n16. Those who have received blood transfusion in 30 days\n17. Those who are deemed insufficient to participate in clinical study by investigators",true,"MALE","55 Years",{"count":80,"type":20},32,[23],"A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846",[84],"Benign Prostate Hypertrophy(BPH)","2026-02-08",{"date":87,"type":36},"2026-02-11",{"date":89,"type":20},"2026-02-23",{"date":91,"type":20},"2026-06-02",{"name":42,"class":43},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":44},"100609519","phase-1-phase-iaib-study-of-ckd-512-alone-and-in-combination-with-pembrolizumab-in-subjects-with-advanced-or-metastatic-solid-tumors-100609519","NCT07215637","Phase Ia\u002FIb Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors","A Multicenter, Open-label, Dose-escalation, Phase Ia\u002FIb Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of CKD-512 Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumor","Inclusion Criteria:\n\n* Histologically confirmed advanced or metastatic solid tumors.\n* Progressive disease after or intolerance to standard therapy and no other effective therapeutic options available.\n* Measurable disease as defined in Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Suitable venous access for the study-required blood sampling, including PK and PD sampling.\n* Adequate clinical laboratory values and other measures\n\nExclusion Criteria:\n\n* Active disease involvement of the central nervous system.\n* Any serious or life-threatening medical condition unrelated to cancer, psychiatric illness, drug or alcohol abuse, that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.\n* Systemic anticancer treatment within the protocol-specified period prior to the first dose.\n* History of any immune-related toxicity that lead to permanent discontinuation of prior anticancer therapy\n* Radiation therapy on a limited area is allowed until 4 weeks prior to the first dose of study drug, provided that the radiated lesion is clinically stable.\n* Prior treatment with investigational agents ≤21 days before the first dose of study drug(s).","18 Years",{"count":102,"type":20},60,[23],"The purpose of this first-in-human (FiH) study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CKD-512 given alone and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors who have failed all standard available therapy.",[27,106],"Metastatic Solid Tumors",[108,109,110,27,106],"A2aR","adenosine A2A receptor","CKD-512","2026-01-29",{"date":113,"type":36},"2026-02-02",{"date":115,"type":36},"2025-10-16",{"date":117,"type":20},"2027-09",{"name":42,"class":43},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":76,"sex":16,"minAge":100,"maxAge":78,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100620479","phase-1-a-study-to-compare-the-pharmacokinetics-pharmacodynamic-immunogenicity-and-safety-of-ckd-706-with-us-dupixent-and-eu-dupixent-in-healthy-adult-participants-100620479","NCT07358156","A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.","A Randomised, Double-blind, Three-arm, Parallel Group, Single Dose, Phase 1 Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.","CKD-706","Inclusion Criteria:\n\n1. Participant is capable of giving signed informed consent\n2. Male and female healthy participant between 18 to 55 years of age (inclusive) at screening, with suitable veins for cannulation or repeated venipuncture.\n3. Body-mass index between 18.5 - 29.9 kg\u002Fm2 (inclusive) with body weight ≥ 50 kg and \\\u003C 95 kg at screening.\n4. Participant agrees to be available for the entire duration of the study\n5. All female participants must have a negative serum pregnancy test at the screening visit and on admission to the Clinical Unit (Day -1).\n6. Female Participants:\n\n   • A female participant is eligible to participate if she is not pregnant, not be lactating and not breastfeeding, and at least one of the following conditions applies\n7. Male Participants • Male participants and their female spouse\u002Fpartners who are of childbearing potential must be using 2 forms of birth control from screening until at least 3 months after the end of study intervention dose.\n\nExclusion Criteria:\n\n1. Participant with history of any clinically important disease or disorder which, may either put the participant at risk during study.\n2. Any clinically important medical\u002Fsurgical procedure or trauma within 8 weeks of the screening visit, or any planned inpatient hospitalisation during the study period.\n3. Participant with prior exposure to dupilumab (Dupixent or biosimilar dupilumab).\n4. Participation in any interventional clinical trial or receipt of any investigational product within 30 days (or \\\u003C 5 half-lives of investigational drug taken) prior to dosing.\n5. Participant with current malignancy or within the past 5 years and suspected malignancy or undefined neoplasms.\n6. Participant with history or presence of chronic gastrointestinal, hepatic, renal, or pancreatic disease or ongoing acute disease in these organs, or any other condition constituting a risk when taking the study intervention.\n7. Participant with diagnosis or history of immunodeficiency or increased susceptibility to severe infections, or a clinically significant infection within 4 weeks of screening.\n8. Any clinically important abnormalities in clinical chemistry, haematology, or urinalysis results at screening or admission, as judged by the Investigator.\n9. Participant with white blood cell count \\\u003C lower limit of normal at screening or admission.\n10. Participant with any clinically significant abnormal finding in vital signs as judged by the Investigator.\n11. Any clinically significant abnormalities on 12-lead ECG at screening or admission (Day -1) to the Clinical Unit, as judged by the Investigator.\n12. Participant with positive screen results for drugs of abuse or alcohol at screening or on admission to the Clinical Unit.\n13. Known or suspected history of alcohol or illicit drug abuse or excessive intake of alcohol within 1 year of screening, as judged by the Investigator.\n14. Participants who smoke more than 5 cigarettes per day or consume equivalent nicotine substitutes, including e-cigarettes or inability to refrain from smoking during the in-house stay period.\n15. Participant has received live vaccine(s) or live attenuated vaccines within 1 month prior to screening or plans to receive such vaccines during the study.\n16. Participant with known helminthic infection, or within 6 months prior to screening.\n17. Participant has a positive test for human immunodeficiency virus antibody or positive results for Hepatitis B surface antigen, anti-hepatitis B core antibody or Hepatitis C virus antibody, except for vaccinated participants or participants with past but resolved hepatitis, at screening.\n18. Participant is unwilling to avoid consumption of coffee and caffeine-containing beverages within 48 hours prior to admission on Day -1 and not consuming caffeine before any outpatient visits.\n19. Participant with excess use of caffeine, which is defined as exceeding 500 mg caffeine\u002Fday (e.g., \\> 5 cups of coffee) within 14 days prior to administration of the study intervention.\n20. Participant has donated blood (\\> 500 mL) or blood products within 56 days prior to admission.\n21. Participant has used over-the-counter medications (including vitamins), prescription medications or herbal remedies from 14 days prior to admission until the End of Study visit.\n22. History of severe allergy\u002Fhypersensitivity or ongoing clinically important allergy\u002Fhypersensitivity, as judged by the Investigator or history of hypersensitivity to monoclonal or polyclonal antibodies. History of allergy or reaction to any formulation components of the study intervention.\n23. Participant is unable to understand the protocol requirements, instructions and study related restrictions, the nature, scope, and possible consequences of the clinical study.\n24. Participant is unlikely to comply with the protocol requirements, instructions and study related restrictions.\n25. Participant has previously been enrolled in this clinical study.\n26. Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.\n27. Involvement of any Chong Kun Dang Pharmaceutical, Parexel or study site employee or their close relatives.",{"count":128,"type":20},519,[23],"This is a randomised, double-blind, three-arm, parallel group, single-dose, Phase 1 comparative study of CKD-706, US-Dupixent, and EU-Dupixent in healthy adult participants.",[132],"Atopic Dermatitis",[125],"2026-01-22",{"date":136,"type":36},"2026-01-23",{"date":138,"type":20},"2026-02-09",{"date":140,"type":20},"2026-11-16",{"name":42,"class":43},2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":44},"100621033","phase-4-evaluate-the-efficacy-and-safety-of-empagliflozin-or-glimepiride-combination-therapy-in-type-2-diabetes-mellitus-patients-100621033","NCT07365358","Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin","EMPAGO","Inclusion Criteria:\n\n* Over 19 years old\n* Type 2 diabetes mellitus\n* Patient who has been taking oral hypoglycemic agents for over 8 weeks\n* Agreement with written informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or secondary diabetes mellitus\n* Patients with complications of severe diabetes such as proliferative diabetic retinopathy\n* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption\n* Patients with abnormal laboratory test results according to the protocol\n* Continuous or non-continuous treatment with insulin for over 7 days within 12 weeks prior to screening\n* History of treatment with corticosteroids within 4 weeks prior to screening",{"count":152,"type":20},200,[154],"PHASE4","The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients",[157],"Diabete Type 2",[157,159],"Empagliflozin",{"date":161,"type":36},"2026-01-26",{"date":163,"type":20},"2026-03",{"date":67,"type":20},{"name":42,"class":43},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":76,"sex":16,"minAge":100,"maxAge":78,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":44},"100612835","phase-1-pharmacokinetic-safety-tolerability-and-immunogenicity-comparison-of-ckd-704-risankizumab-biosimilar-with-eu-approved-skyrizi-and-us-licensed-skyrizi-in-healthy-adult-participants-100612835","NCT07258745","Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants","A Randomized, Double-Blind, Single-Dose, Parallel-Group, Three-Arm Trial to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity Profiles of CKD-704 (Risankizumab Biosimilar), EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants","Inclusion Criteria:\n\n* Capability of giving signed informed consent and complying with the requirements and restrictions listed in the ICF and Protocol\n* Healthy male or female, 18 to 55 years (inclusive) at the time of signing the ICF\n* smokes ≤ 10 cigarettes per week within 3 months of screening\n* abstain from alcohol from 48 hours prior to study intervention administration and keeping alcohol consumption within WHO limits (more than 14 units per week spread over 3 or more days, equivalent to 6 pints of average strength beer or 6 medium glasses \\[175 mL\\] of wine)\n* have acceptable venous access for blood collection\n* Female participants are eligible to participate if they are not pregnant, not breastfeeding\n* Male participants must refrain from donating sperm from screening (signing the ICF) until at least 30 days after EOS visit\n* All participants must be willing to use effective\u002Fhighly effective methods of contraception during the study period\n* Participants are willing and able to be confined to the clinical unit prior to and during the study intervention administration and required follow-up periods.\n\nExclusion Criteria:\n\n* History of previous exposure to any anti-IL-12\u002F23 or anti-IL-23 treatment\n* History of relevant drug and\u002For food allergies\n* History of hypersensitivity to Skyrizi or their constituents\n* Presence of psychiatric disorders or altered mental status precluding understanding of the informed consent process and\u002For completion of the necessary procedures\n* Medical history, findings of physical examination\u002Flaboratory tests indicate a clinically significant disorder, condition, or disease that, in the opinion of the Investigator would pose a risk to participant safety\n* Major surgery within 12 weeks prior to the randomization into the study\n* Documented active or suspected malignancy or history of malignancy within 5 years prior to screening\n* Positive tests for hepatitis B surface antigen, Hepatitis B core antibody, hepatitis C virus antibody, or human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening\n* Positive test for severe acute respiratory syndrome coronavirus 2 on admission (optional)\n* Any current active infections or any recent history (within 1 week prior to study intervention administration) of active infections\n* Participant has a history of tuberculosis (TB) diagnosis or evidence of active or latent infection with Mycobacterium tuberculosis\n* Abnormal hepatic, renal, or hematological laboratory tests. In such cases, the assessment may be repeated once at screening and admission. The Investigator will check reassessment results to decide if the value is clinically significant and if participant is eligible to receive the treatment\n* Any other laboratory value outside the reference range that the Investigator considers to be of clinical significance\n* Abnormal vital signs(Systolic blood pressure \\\u003C 90 mmHg or \\> 140 mmHg, Diastolic blood pressure \\\u003C 50 mmHg or \\> 90 mmHg, Heart rate \\\u003C 45 or \\> 100 beats per minute)\n* Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG\n* Any past or concurrent medical conditions, or clinically important active infection that could potentially increase the participant's risks or that would interfere with the study evaluation, procedures, or study completion\n* Have used any prescription or non-prescription medicines or vitamins within 7 days or 5 half-lives (whichever is longer) of admission, unless in the Investigator's opinion will not affect determination of safety or other study assessments\n* Male or females participating in any other clinical trial at the time of consenting\n* Have received any investigational drug within 30 days prior to screening, with minimal washout of at least 5-half-lives of any previous investigational drug, whichever is longer\n* Have received live vaccines during the past 4 weeks before screening or have the intention to receive vaccination during the 21-week treatment and assessment period\n* Participant has donated blood (\\> 500 mL) or blood products within 2 months (56 days) prior to screening\n* History of drug abuse or alcohol abuse as judged by the Investigator or designee\n* Participant is affiliated with the site or Sponsor and\u002For may be considered to be consenting under duress\n* Participant is unlikely to co-operate with the requirements of the study",{"count":174,"type":20},213,[23],"This is a Phase 1, first-in-human (FIH), randomized, double-blind, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi in healthy adult participants.",[178],"Psoriasis",[178],"2025-12-15",{"date":182,"type":36},"2025-12-19",{"date":184,"type":36},"2025-11-26",{"date":186,"type":20},"2026-09-30",{"name":42,"class":43},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":44},"100565564","phase-3-phase-3-trial-to-evaluate-the-efficacy-and-safety-of-ckd-202a-100565564","NCT06643819","Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","A Randomized, Double-blind, Active-controlled, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","Inclusion Criteria:\n\n* Participants who are 19 years old or older.\n* Participants who have voluntarily decided to participate in this clinical trial and signed ICF.\n\nExclusion Criteria:\n\n* Participants with a history of secondary hypertension or suspected secondary hypertension.\n* Participants with a orthostatic hypotension.\n* Participants who require combination administration of antihypertensive drugs other than clinical trial drugs during the clinical trial participation period.\n* Participants with type 1 diabetes or poorly controlled diabetes.\n* Participants who treated other clinical trial drugs within 4 weeks of screening visit.\n* Participants with a history of drug or alcohol abuse or suspected patient within 24 weeks as of the time of screening\n* Pregnant women, lactating women, or Subjects who do not agree to use appropriate contraception during the clinical trial period and for two weeks after the end of administration of the last clinical trial drug\n* Participants who are unable to participate in this clinical trial at the discretion of the investigator.",{"count":196,"type":20},324,[198],"PHASE3","Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)",[201],"Essential Hypertension","2025-12-04",{"date":204,"type":36},"2025-12-11",{"date":206,"type":36},"2024-10-14",{"date":208,"type":20},"2026-12-31",{"name":42,"class":43},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":44},"100588496","phase-4-optimize-immunosuppressive-therapy-using-everolimus-and-low-dose-calcineurin-inhibitors-in-heart-transplant-patients-in-korea-100588496","NCT06942156","Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","A Prospective, Multicenter, Open-Label, Randomized, Comparative, Phase 4 Trial to Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea","OPTIMIZE-HTx","Inclusion Criteria:\n\n1. Over 19 years old\n2. Patients with stable heart transplant graft function at least 28\\~100 days post transplant.\n3. Patients who are appropriate for combination therapy with Everolimus and Calcineurin inhibitor (CNI) at the investigator's discretion\n\nExclusion Criteria:\n\n1. Recipients who have had a prior organ transplant, or who underwent a heart transplant with the simultaneous transplantation of another organ.\n2. Recipients of heart from ABO-incompatible donor\n3. Recipients of heart from the donor aged 70 or older",{"count":19,"type":20},[154],"The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.",[222],"Heart Transplant",[224,225],"Heart transplant","Everolimus","2025-04-21",{"date":228,"type":36},"2025-04-24",{"date":230,"type":20},"2025-08-14",{"date":232,"type":20},"2030-12",{"name":42,"class":43},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":77,"minAge":100,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":44},"100586547","phase-3-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-ckd-843-in-male-patients-with-androgenetic-alopecia-100586547","NCT06916793","A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia","A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-843 in Male Patients With Androgenetic Alopecia","Key Inclusion Criteria:\n\n* Male of age 18-50 years\n* Clinical Diagnosis of Androgenetic Alopecia\n* Written informed consent\n\nKey Exclusion Criteria:\n\n* Other types of Alopecia or other diseases that can cause hair loss\n* Clinically significant scalp disease such as seborrheic dermatitis or psoriasis\n* Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator\n* Participants who do not agree to use contraception during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose","50 Years",{"count":243,"type":20},288,[198],"This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia",[247],"Androgenetic Alopecia","2025-04-01",{"date":250,"type":36},"2025-04-08",{"date":252,"type":20},"2025-04-30",{"date":254,"type":20},"2027-09-17",{"name":42,"class":43},{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":266,"phases":4,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":44},"100580514","korean-study-on-safety-and-effectiveness-of-oad-triple-therapy-in-type-2-diabetes-100580514","NCT06838286","Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes","A Multicenter, Prospective, Non-interventional Observation Study to Evaluate the Safety and Effectiveness of OAD Triple Therapy in Korean Type 2 Diabetic Mellitus Patients","TRIO","Inclusion Criteria:\n\n1. Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment.\n2. Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment.\n3. 7.0% ≤ HbA1c \\\u003C 10.0% based on laboratory tests performed within 4 weeks of enrollment.\n4. Voluntarily give written informed consent after being told about the study.\n\nExclusion Criteria:\n\n1. Patients with type 1 diabetes and secondary diabetes.\n2. Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment.\n3. Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study.\n4. End-stage renal disease and hemodialysis patients.\n5. diabetic ketoacidosis Patients.\n6. Pregnant and lactating women.\n7. Patients who are contraindicated by any of the \"Precautions for Use\" in the license for the drug being administered during the study, given the observational nature of the study under routine practice.\n8. Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients.\n9. Anyone else deemed by the investigator to be unsuitable for participation in the study.",{"count":265,"type":20},10000,"OBSERVATIONAL","A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.",[269],"Diabetes Mellitus, Type 2",[271,272,273,274],"Type 2 diabetes mellitus","Korean patients","Observational study","OAD triple therapy","2025-02-18",{"date":277,"type":36},"2025-02-20",{"date":279,"type":36},"2024-03-16",{"date":281,"type":20},"2029-12-31",{"name":42,"class":43},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":21,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":4},"100553943","phase-1-to-evaluate-the-food-effect-on-pharmacokinetic-profiles-and-safety-in-healthy-volunteers-100553943","NCT06492655","To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers","A Randomized, Open-label, Single Dose, Crossover, Phase 1 Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-383 in Healthy Volunteers","Inclusion Criteria:\n\n* Healthy adults aged 19 to 54 years\n* BMI measurement result is 18.0 kg\u002Fm2 to 30 kg\u002Fm2\n* Written informed consent\n* Other inclusion criteria, as defined in the protocol\n\nExclusion Criteria:\n\n* who has taken drug metabolism enzyme induction and inhibitory drugs, such as barbitale drugs, within 30 days prior to the start of the trial (Period\n\n  1 administration)\n* Other exclusive criteria, as defined in the protocol","54 Years",{"count":292,"type":20},28,[23],"This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers",[296],"Type 2 Diabetes Mellitus","2024-07-09",{"date":299,"type":36},"2024-07-10",{"date":301,"type":20},"2024-07-04",{"date":303,"type":20},"2024-08-08",{"name":42,"class":43},""]